Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6977670 | 0.87 | PKM (0.53) | SMN1; SMN2TP53NPC1RAB9APKM | |
| SCHEMBL6968232 | 0.84 | PKM (0.63) | SMN1; SMN2TP53NPC1RAB9APKM | |
| SCHEMBL3997492 | 0.81 | RAB9A (0.63) | SMN1; SMN2TP53NPC1RAB9APKM | |
| SCHEMBL7861771 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2TP53NPC1RAB9APKM | |
| Acetic Acid SCHEMBL9385119 | 0.80 | NPC1 (0.65) | SMN1; SMN2NPC1RAB9APKML3MBTL1 | |
| SCHEMBL3496975 | 0.80 | PKM (0.51) | SMN1; SMN2NPC1RAB9APKML3MBTL1 | |
| SCHEMBL12090778 | 0.77 | MAPT (0.66) | SMN1; SMN2TP53NPC1RAB9AL3MBTL1 | |
| SCHEMBL14530530 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9APKML3MBTL1 | |
| SCHEMBL12919472 | 0.76 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9APKMMAPT | |
| SCHEMBL12919371 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | SMN1; SMN2 3945/4885TP53 3284/4885PARP10 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.